SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
GH reported Third Quarter 2026 results. The stock moved -1.7% on the print.
GHearnings

Earnings reactions, page 5

Guardant Health, Inc. (GH) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Reported total revenue of $361.0 million for the third quarter of 2026, an increase of 36% compared to $265.2 million for the third quarter of 2025.
  • Generated non-GAAP gross margin of 67% for the third quarter of 2026, compared to 66% for the third quarter of 2025.
  • Reported Oncology revenue of $231.3 million and 117,000 oncology tests for the third quarter of 2026.
  • Reported Screening revenue of $67.6 million and 83,000 Shield tests for the third quarter of 2026.
  • Reported GAAP net loss of $124.4 million, or $0.93 per share, for the third quarter of 2026.
  • Reported non-GAAP net loss of $38.8 million, or $0.29 per share, for the third quarter of 2026.

Guidance

  • Full year 2026 revenue is expected to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
  • Oncology revenue is expected to grow approximately 30% and Oncology volume is expected to grow over 50%.
  • Biopharma & Data revenue growth is expected to be in the low double-digit range.
  • Screening revenue is expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests.
  • Full year 2026 non-GAAP gross margin is expected to be 65%.
  • Total non-GAAP operating expenses are expected to be in the range of $1.105 to $1.125 billion.
  • Full-year free cash flow burn is expected to be $205 million to $220 million.

Price and volatility reaction

The stock moved -1.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -37.9 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release153.432026-11-05
Close after release150.872026-11-06
Realised move-1.7%close to close
30d ATM IV change-37.9 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →